Tenderwize
Retour à la recherche

Open-house drug rebate agreements Mecklenburg-Vorpommern

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 179 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Mecklenburg-Vorpommern

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice text says contract conclusion is possible until 21.02.2026, but the publication date is 11.02.2026 and the n...

A document URL is provided, but no full procurement document text beyond the TED XML notice was analyzed.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Open-House pharmaceutical rebate agreements under § 130a(8c) SGB V for the Mecklenburg-Vorpommern region.
  • Supply of oncology-related parenteral preparations made from finished medicinal products for immediate physician use in pharmacies.
Afficher le résumé complet

This is an Open-House pharmaceutical rebate agreement notice for Mecklenburg-Vorpommern, covering three active substances: Bevacizumab, Rituximab, and Trastuzumab. The lead buyer is AOK Nordost, with several other health insurers listed as participating buyers. The model is non-exclusive, with no selection among bidders, and contracts are offered on identical, non-negotiable terms to all eligible pharmaceutical companies. Submission is allowed electronically and by signed paper originals; the notice states that documents are available via DTVP, but the extracted procurement documents were not fully analyzed beyond the TED XML notice text. The estimated contract value is not provided.

Risques

The notice text says contract conclusion is possible until 21.02.2026, but the publication date is 11.02.2026 and the n...

A document URL is provided, but no full procurement document text beyond the TED XML notice was analyzed.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract signatory must have authority shown in the commercial register extract; otherwise a power of attorney must be provided.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit the signed contract, the completed file 'OHV_8c_Mecklenburg-Vorpommern_Festlegung_[Wirkstoffname]_PZN', and the signed reliability declaration.

Acheteur

Localisation

Potsdam, DEU

Site web

www.aok.de

Identifiant

DE275390265

Activité

Health

Lots (3)

LOT-0001

Bevacizumab

Open-House rebate agreement for Bevacizumab (ATC L01FG01) for the Mecklenburg-Vorpommern region. The notice states this is not a competitive award procedure but a non-exclusive Open-House model for pharmaceutical companies supplying parenteral oncology preparations for immediate physician use in pharmacies. Contract terms are identical and non-negotiable. The lot-specific selection criteria in the structured data are an expression of interest, reliability declaration, and in the XML notice also current business liability insurance and a trade register extract not older than 2 years.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

LOT-0002

Rituximab

Open-House rebate agreement for Rituximab (ATC L01FA01) for the Mecklenburg-Vorpommern region. The notice states this is a non-exclusive Open-House model for pharmaceutical companies and not a selection-based procurement. Lot-specific eligibility in the structured data is a reliability declaration; the XML notice also mentions current business liability insurance and a trade register extract not older than 2 years.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

LOT-0003

Trastuzumab

Open-House rebate agreement for Trastuzumab (ATC L01FD01) for the Mecklenburg-Vorpommern region. The notice states this is a non-exclusive Open-House model for pharmaceutical companies and not a selection-based procurement. Lot-specific eligibility in the structured data is a sanctions declaration; the XML notice also mentions current business liability insurance and a trade register extract not older than 2 years.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

Détails de la procédure

Date de publication
11 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
103191-2026

Documents (2)

Appels d'offres similaires